About Paul Berns
Paul Berns is an officer and director at Neumora Therapeutics.
Form D filings name Paul Berns as a director at Metsera.
Paul Berns reports to the SEC as a director, officer or major shareholder of 12 public companies, including Kardigan (KARD), Lyell Immunopharma (LYEL) and Metsera (MTSR).
Paul Berns first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Paul Berns in the role, so the role may have started earlier or lasted longer.
NI
Neumora Therapeutics, Inc.
Officer and director
2023 – 2026 · Public company (NMRA)
KI
Kardigan, Inc.
Director and 10% owner
2026 · Public company (KARD)
LI
Lyell Immunopharma, Inc.
10% owner
2025 – 2026 · Public company (LYEL)
UI
Unity Biotechnology, Inc.
Director
2018 – 2024 · Public company (UBX)
EI
EQRx, Inc.
Director
2021 – 2023 · Public company (EQRX)
JP
Jazz Pharmaceuticals plc
Director
2010 – 2021 · Public company (JAZZ)
YI
Yarrow Bioscience, Inc.
Director
2018 – 2019 · Public company (YARW)
AI
Anacor Pharmaceuticals, Inc.
President and CEO, director
2012 – 2016 · Public company (ANAC)
XI
Xenoport Inc.
Director
2006 – 2016 · Public company (XNPT)
CI
Cellectar Biosciences, Inc.
Director
2014 – 2016 · Public company (CLRB)
AI
Allos Therapeutics Inc.
Chief Executive Officer
2006 – 2012 · Public company (ALTH)
Key Colleagues at Startups
The people Paul Berns works with at each company, as listed on that company's latest Form D.
Metsera, Inc. · Form D, Nov 20, 2024
KB
Kristina Burow
Director
CV
Christopher Visioli
Executive officer
BH
Brian Hubbard
Executive officer
CB
Christopher Bernard
Chief Executive Officer and director
SM
Steven Marso
Executive officer
CM
Clive Meanwell
Director
JP
Joshua Pinto
Director